PURPOSE OF REVIEW: Long-acting formulations of antiretrovirals have the potential to reshape the treatment paradigm for HIV infection. Emerging evidence demonstrates efficacy and safety of two drug regimens for the treatment of HIV infection. This review focuses on recent advances with long-acting cabotegravir and rilpivirine administered intramuscularly every 4 weeks for the treatment of HIV infection in virologically suppressed patients. RECENT FINDINGS: Despite the development of complete, orally administered single tablet regimens with improved efficacy, side effects, tolerability, with an improved drug interaction potential, patients still have challenges adhering to daily oral therapy. Psychological factors including HIV stigma contribute to patient's ability to adhere to treatment. Newer nonoral treatment regimens may improve adherence, patient satisfaction and limit HIV stigma. SUMMARY: A two-drug intramuscular regimen of cabotegravir and rilpivirine has advanced through phase 3 clinical development. Results from studies assessing safety, virologic, pharmacologic, and drug interactions have been completed. Larger efficacy studies have demonstrated noninferiority of switching virologically suppressed patients from a three drug daily oral regimen to a two-drug intramuscular regimen administered Q4W with long-term data to 160 weeks demonstrating durability of treatment response.
PURPOSE OF REVIEW: Long-acting formulations of antiretrovirals have the potential to reshape the treatment paradigm for HIV infection. Emerging evidence demonstrates efficacy and safety of two drug regimens for the treatment of HIV infection. This review focuses on recent advances with long-acting cabotegravir and rilpivirine administered intramuscularly every 4 weeks for the treatment of HIV infection in virologically suppressed patients. RECENT FINDINGS: Despite the development of complete, orally administered single tablet regimens with improved efficacy, side effects, tolerability, with an improved drug interaction potential, patients still have challenges adhering to daily oral therapy. Psychological factors including HIV stigma contribute to patient's ability to adhere to treatment. Newer nonoral treatment regimens may improve adherence, patient satisfaction and limit HIV stigma. SUMMARY: A two-drug intramuscular regimen of cabotegravir and rilpivirine has advanced through phase 3 clinical development. Results from studies assessing safety, virologic, pharmacologic, and drug interactions have been completed. Larger efficacy studies have demonstrated noninferiority of switching virologically suppressed patients from a three drug daily oral regimen to a two-drug intramuscular regimen administered Q4W with long-term data to 160 weeks demonstrating durability of treatment response.
Authors: Karine Dubé; Danielle M Campbell; Kelly E Perry; John T Kanazawa; Parya Saberi; John A Sauceda; Tonia Poteat; David Evans Journal: AIDS Res Hum Retroviruses Date: 2020-09-14 Impact factor: 2.205
Authors: Zahra Reynolds; Suzanne M McCluskey; Mahomed Yunus S Moosa; Rebecca F Gilbert; Selvan Pillay; Isaac Aturinda; Kevin L Ard; Winnie Muyindike; Nicholas Musinguzi; Godfrey Masette; Pravi Moodley; Jaysingh Brijkumar; Tamlyn Rautenberg; Gavin George; Brent A Johnson; Rajesh T Gandhi; Henry Sunpath; Vincent C Marconi; Mwebesa Bosco Bwana; Mark J Siedner Journal: HIV Med Date: 2021-11-09 Impact factor: 3.094
Authors: Susan Swindells; Thomas Lutz; Lelanie Van Zyl; Norma Porteiro; Matthias Stoll; Essack Mitha; Alyssa Shon; Paul Benn; Jenny O Huang; Conn M Harrington; Kai Hove; Susan L Ford; Christine L Talarico; Vasiliki Chounta; Herta Crauwels; Rodica Van Solingen-Ristea; Simon Vanveggel; David A Margolis; Kimberly Y Smith; Kati Vandermeulen; William R Spreen Journal: AIDS Date: 2022-02-01 Impact factor: 4.632